Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 9Phase 3 7Phase EARLY_PHASE1 1Phase 2/3 1Phase 1/2 1

Status

Completed 4Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 7OTHER 4NETWORK 1

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 5Tumor-Agnostic 1Thoracic 1

Conditions

Pancreatic Neoplasms 4Small Cell Lung Carcinoma 1Neoplasms 1Metastatic Adenocarcinoma of the Pancreas 1

Interventions

Carboplatin 314Paclitaxel 302Cisplatin 250Docetaxel 237pembrolizumab 230Gemcitabine 213Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 120Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 92Prednisone 91Oxaliplatin 89atezolizumab 73Leucovorin 71durvalumab 69130-nm albumin-bound paclitaxel 67Injections 64Lenalidomide 63Irinotecan 60Bortezomib 55Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × irinotecan sucrosofate × Clear all
NCT07409272 2026-05-18

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Astellas Pharma Inc

Phase 3 Recruiting
614 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06625320 2026-04-27

RASolute 302

Revolution Medicines, Inc.

Phase 3 Active not recruiting
500 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04083235 2026-04-20

NAPOLI 3

Ipsen

Phase 3 Completed
770 enrolled 13 charts 1 FDA
Gastrointestinal

Metastatic Adenocarcinoma of the Pancreas

NCT03088813 2025-02-19

RESILIENT

Ipsen

Phase 3 Completed
491 enrolled 24 charts
Thoracic

Small Cell Lung Carcinoma

NCT06571461 2024-08-27

Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer

CSPC Ouyi Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
408 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT03665441 2022-10-18

Trybeca-1

ERYtech Pharma

Phase 3 Completed
512 enrolled 19 charts
Tumor-Agnostic

Neoplasms

NCT01494506 2016-06-17

NAPOLI-1

Merrimack Pharmaceuticals

Phase 3 Completed
417 enrolled 20 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡